Peptide therapy is one of the most aggressively marketed categories in wellness medicine and one of the least clearly explained. This page tries to explain it properly, including the parts that are unsettled.
Medically reviewed by Kent Cohen, MD, FACEP — Medical Director, Balanced Bodies: Longevity + Wellness Clinic. Last reviewed October 2026.
What a peptide actually is
A peptide is a short chain of amino acids — the same building blocks that make up proteins, just fewer of them. Your body produces many of its own, and they act as signalling molecules: insulin is a peptide, as is the GLP-1 that semaglutide mimics.
So “peptide therapy” is not one treatment. It is a category containing compounds with very different mechanisms, very different evidence, and very different regulatory positions. Treating them as a single thing is the first mistake most marketing makes.
Where the evidence is strongest
Some peptide medications are FDA-approved, well studied and unambiguous. Insulin. GLP-1 receptor agonists such as semaglutide and tirzepatide. Certain growth hormone-releasing analogues approved for specific diagnoses.
These are proper medications with approved indications, and when people talk about peptides having strong evidence, these are what they mean.
Where it is much weaker
The compounds driving most of the current interest — BPC-157, TB-500 and similar — are in a different position.
Most of the research is preclinical: cell cultures and animal studies, frequently in rodents. Those studies are often genuinely interesting. They are also not the same as human clinical trials, and the history of medicine is full of compounds that performed well in rats and did nothing in people.
Human data is limited. Claims about healing, recovery and tissue repair that you will find across the internet substantially outrun what has been demonstrated in humans. Anyone presenting these as established is overstating the case.
Where the regulation stands
This has moved during 2026 and the position is genuinely unsettled.
In 2023 the FDA placed BPC-157 in Category 2 of its 503A bulk drug substances review — the category for substances raising significant safety concerns, which in this case centred on immunogenicity and impurities.
In April 2026 the FDA removed BPC-157, along with several other peptides, from Category 2. That eased the restriction but did not place it in Category 1, which is the category that supports compounding.
In July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted narrowly — 8 to 6 — to recommend adding BPC-157 to Category 1, with TB-500 receiving the same margin. Those votes are advisory and non-binding. Formal listing requires a separate rulemaking process with a public comment period, which has not concluded.
So as things stand, neither compound is on the 503A list, and the legal basis for compounding them is unresolved rather than settled. Neither is FDA-approved, and neither has been reviewed by the FDA for safety or effectiveness for the uses they are commonly marketed for.
Any clinic presenting these as approved, or as straightforwardly legal to compound, is ahead of the facts.
What to ask before starting peptide therapy anywhere
- Which specific peptide, and what is its current regulatory status?
- What human evidence exists for this use, as opposed to animal evidence?
- Which pharmacy is preparing it, and on what basis?
- What is being monitored while I take it?
- What would make us stop?
If a clinic cannot answer the first two, that is the answer.
Our position
Peptide therapy at our Marietta clinic begins with a medical evaluation rather than a preselected package. Your provider reviews your history, medications, symptoms and goals, and orders lab work where appropriate, before recommending anything.
We tell patients plainly when a compound is not FDA-approved and when the evidence is preclinical rather than clinical. We would rather have that conversation than sell something on the strength of a rat study.
If what you are actually looking for is better recovery, more energy or improved body composition, it is worth knowing that the unglamorous interventions — sleep, protein, resistance training, correcting a genuine deficiency, and treating an underlying hormonal or metabolic problem — have considerably better evidence behind them than most of this category. We will say so at the consultation, which is free.
More on the peptide therapy page.
Book a free consultation or call (678) 919-4845.
Further reading
This article is general information, not medical advice. Regulatory status described here reflects the position as of October 2026 and may change. Compounded preparations are not FDA-approved and have not been reviewed by the FDA for safety or effectiveness for these uses. Individual responses vary and specific outcomes are not guaranteed.
